Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

CPG 7909 in Melanoma


CPG 7909 Injection With or Without Chemotherapy for the Treatment of Stage III b/c or IV Melanoma: A Randomized, Multi-Center, Open Label, Parallel Group, Active-Controlled, Phase II/III Study




The primary objective of this Phase II/III study is to assess the anti-neoplastic activity, as determined by overall response rate (complete plus partial responses) according to the RECIST criteria of CPG 7909 Injection alone at two doses and in combination with DTIC. The study will also gather data on the response of patients with metastatic melanoma to a regimen of CPG 7909 compared to CPG 7909 plus chemotherapy.

Study Status: Completed


Condition Intervention Phase
Melanoma Drug: CPG 7909
Drug: DTIC Chemotherapy
Phase 2/Phase 3

Verified by Pfizer October, 2008

Sponsored by: Pfizer
Information provided by: Pfizer identifier: NCT00070642

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study

Cleveland Clinic
Cleveland, Ohio 44195
United States


This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit
  Information obtained from on
Link to the current record.

Cleveland Clinic Mobile Site